- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05466968
Intervention of Suxiao Jiuxin Pill on Instability of Vulnerable Plaque in Acute Myocardial Infarction
July 18, 2022 updated by: Xiaolu Li
Clinical Trial of Suxiao Jiuxin Pill on the Instability of Vulnerable Plaque With Integrated Traditional Chinese Medicine and Western Medicine in Acute ST-segment Elevation Myocardial Infarction(STEMI) Patient
The incidence of cardiovascular disease is still high in China under the condition of non-standard treatment of Western medicine.
Acute coronary plaque rupture and thrombosis is an extreme manifestation of instability of "vulnerable plaque", which is the result of the joint action of multiple factors.
The intervention of unstable plaque reversal from multiple factors is inherently reasonable.
Compared with the treatment of thrombosis and unstable plaque in western medicine, quick acting Jiuxin Pill can not only calm and relieve pain for pain and other symptoms, but also regulate immune inflammation and metabolic disorder, improve microcirculation and anti myocardial ischemia.
In order to evaluate the efficacy, safety and modern scientific basis of Suxiao Jiuxin Pill in acute myocardial infarction (AMI), the investigators designed this study.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Under the condition of standardized western medicine treatment, the incidence and disability rate of cardiovascular disease in China is still high.
There has been a wealth of clinical practice in the treatment of acute myocardial infarction with traditional Chinese medicine, and clinical evidence-based exploration is an inevitable trend.
Suxiao Jiuxin Pill is a classic old medicine, but large-scale randomized controlled trial are still needed to consolidate the efficacy, safety and modern scientific basis in acute myocardial infarction (AMI).
This pilot single center standardization research is the most basic support and exploration.
This project can enhance the influence of Suxiao Jiuxin pills in the context of modern science, which will help the products to be more widely used in Chinese and western hospitals, benefit more patients, reduce the health economics cost of patients with acute ischemia of coronary heart disease at home and abroad, and reduce the social burden.
From the perspective of local "vulnerable plaque" instability and "vulnerable patients" systemic inflammation outbreak driving plaque rupture, this study aims to clarify the effect of Suxiao Jiuxin Pill on thrombotic lesions, systemic and clinical short-term prognosis in patients with acute ST segment elevation myocardial infarction (STEMI) from multi-target and multi-component.
This study provides evidence for the mechanism of Suxiao Jiuxin Pill in the comprehensive prevention and treatment of pathophysiological disorders in STEMI patients.
Study Type
Interventional
Enrollment (Anticipated)
116
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Nannan Li
- Phone Number: 15865266456
- Email: 1003023531@qq.com
Study Locations
-
-
-
Jinan, China, +86250001
- Xiaolu Li
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Between the ages of 18-75;
- Meet the diagnosis of AMI global definition version 4,admit from emergency department;
- Prepare for emergency coronary angiography and PCI reperfusion therapy;
- Volunteer to participate in this study and have signed an informed consent form.
Exclusion Criteria:
- AMI with cardiogenic shock (Killip grade ≥ grade III) and no response to vasopressin;
- AMI complicated with severe arrhythmia (persistent ventricular tachycardia, ventricular fibrillation);
- AMI complicated with mechanical complications (ventricular septal perforation, papillary muscle rupture, intracardiac thrombus, ventricular free wall rupture);
- Severe systemic diseases (immune system diseases, sepsis and other serious infections, blood system diseases, massive hemorrhage caused by anticoagulation and antithrombotic therapy, and severe organ failure (such as ALT ≥ 3 ULN, cr> 134 μ Mol/l (2mg/dl) or egfr<45ml/min/1.73m2);
- History of cerebral hemorrhage and cerebral aneurysm within 3 months;
- Mental patients;
- Malignant tumor or other pathophysiological condition with expected survival less than 1 year;
- Those who are allergic to the drug components of this study;
- Pregnant or lactating women;
- Patients who have participated in clinical trials of other drugs within 3 months before enrollment or took other Chinese patent medicines with similar effects within the first three months of enrollment;
- Other diseases with clinical significance that may cause serious danger to patients.
- In TCM syndrome types, Qi deficiency, Yang deficiency and other deficiency syndrome types, and cold congealing heart pulse syndrome types in positive syndrome types.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Suxiao Jiuxin Pills
Suxiao Jiuxin Pills prescription (15 pills loading does, maintenance 6 pills each time, three times a day.) for 90 days
|
Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).
Other Names:
|
PLACEBO_COMPARATOR: The placebo of Suxiao Jiuxin Pills
The placebo of Suxiao Jiuxin Pills prescription (15 pills loading does, maintenance 6 pills each time, three times a day.) for 90 days
|
The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of MMP-9
Time Frame: Up to 30 minutes after administration
|
MMP-9 measure by Elisa
|
Up to 30 minutes after administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of TIMI myocardial perfusion (TMP) of "criminal vessel".
Time Frame: Up to 30 minutes after administration
|
TMP measure by CAG
|
Up to 30 minutes after administration
|
Changes in the local morphology of vulnerable plaque
Time Frame: Up to 30 minutes after administration
|
Proportion of lipid / necrotic core in plaque area by IVUS
|
Up to 30 minutes after administration
|
Changes of PCSK9 in vulnerable plaque
Time Frame: Up to 30 minutes after administration
|
PCSK9 measure by Elisa
|
Up to 30 minutes after administration
|
Expression changes of local SMC-FC transformation indexes in vulnerable plaque
Time Frame: Up to 30 minutes after administration
|
LOX-1 measure by Elisa
|
Up to 30 minutes after administration
|
Expression changes of Local EC function index of vulnerable plaque
Time Frame: Up to 30 minutes after administration
|
iNOS measure by Elisa
|
Up to 30 minutes after administration
|
Expression changes of Local angiogenic factors in vulnerable plaque
Time Frame: Up to 30 minutes after administration
|
VEGF measure by Elisa
|
Up to 30 minutes after administration
|
Expression changes of indicators associated with vulnerable plaque rupture events
Time Frame: Up to 30 minutes after administration
|
TNF-a measure by Elisa
|
Up to 30 minutes after administration
|
Changes in coagulation related indicators in vulnerable plaque
Time Frame: Up to 30 minutes after administration
|
Coagulation factor X measure by Elisa
|
Up to 30 minutes after administration
|
The changes of inflammation related indicators
Time Frame: 3 months after PCI
|
IL-6 by Omics research
|
3 months after PCI
|
Changes of remodeling indexes
Time Frame: 3 months after PCI
|
LVEF measure by UCG
|
3 months after PCI
|
Changes in the incidence of MACE
Time Frame: 3 months after PCI
|
Recurrent unstable angina pectoris, non fatal myocardial infarction, cardiogenic death, revascularization (pci+cabg), stroke, heart failure requiring hospitalization and all-cause death measure by data statistics
|
3 months after PCI
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Xiaolu Li, The First Affiliated Hospital Of Shandong First Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
August 1, 2022
Primary Completion (ANTICIPATED)
June 1, 2025
Study Completion (ANTICIPATED)
June 1, 2027
Study Registration Dates
First Submitted
July 12, 2022
First Submitted That Met QC Criteria
July 18, 2022
First Posted (ACTUAL)
July 20, 2022
Study Record Updates
Last Update Posted (ACTUAL)
July 20, 2022
Last Update Submitted That Met QC Criteria
July 18, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- YXLL-KY-2022(030)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myocardial Infarction
-
Henry Ford Health SystemAbiomed Inc.Enrolling by invitationAcute Myocardial Infarction | Cardiogenic Shock | STEMI | NSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial Infarction | NSTEMI | Acute Myocardial Infarction With ST Elevation | Acute Myocardial Infarction of Right Ventricle (Disorder) | Acute Myocardial Infarction of Left VentricleUnited States
-
Jordan Collaborating Cardiology GroupCardiovascular Academy GroupTerminatedTriggers of Acute Myocardial Infarction | Time of Onset of Acute Myocardial Infarction | Long-term Prognosis After Acute Myocardial InfarctionJordan
-
Recardio, Inc.CompletedAcute Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Myocardial IschemiaNetherlands, Hungary, Austria, Poland, Belgium
-
Medical Center of South ArkansasWithdrawnAcute Coronary Syndrome | Acute ST Segment Elevation Myocardial InfarctionUnited States
-
Yuan's General HospitalKaohsiung Veterans General Hospital.; Sin-Lau HospitalUnknownAcute Myocardial Infarction, of Inferolateral Wall | Acute Myocardial Infarction, of Inferoposterior WallTaiwan
-
Aristotle University Of ThessalonikiRecruitingCardiovascular Diseases | Acute Coronary Syndrome | Acute Myocardial Infarction | Metabolic DisturbanceGreece
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
-
Sheba Medical CenterCompletedNon ST Elevation Myocardial Infarction | Acute Coronary SyndromesIsrael
-
Medstar Health Research InstituteWithdrawnST-elevation Myocardial Infarction | Acute Myocardial InfarctionUnited States
-
Hennepin Healthcare Research InstituteSiemens HealthineersActive, not recruitingAcute Coronary Syndrome | Acute Myocardial InfarctionUnited States
Clinical Trials on Suxiao Jiuxin Pills
-
Guangzhou University of Traditional Chinese MedicineNot yet recruitingAcute Coronary Syndrome
-
Singapore Institute of TechnologyAMILI Pte. Ltd.Active, not recruitingGastrointestinal Microbiome | Protein DigestionSingapore
-
Beijing Tiantan HospitalTasly Pharmaceutical Group Co., LtdActive, not recruiting
-
China National Center for Cardiovascular DiseasesFuwai Yunnan Cardiovascular HospitalRecruitingCoronary Heart Disease | Medicine, Chinese TraditionalChina
-
University of Maryland, BaltimoreNot yet recruitingChronic Pain | Headache
-
Virginia Commonwealth UniversityCompleted
-
Tasly Pharmaceutical Group Co., LtdCompleted
-
Dalian UniversityUnknown
-
Dongzhimen Hospital, BeijingNot yet recruiting